Liquid and low melting coating for stents
View Patent ↗Stents with coatings comprising a combination of a restenosis inhibitor comprising an HMG-CoA reductase inhibitor and a carrier. Also provided are methods of coating stents with a combination of an HMG-CoA reductase inhibitor and a carrier. A preferred example of a restenosis inhibitor is cerivastatin. The stent coatings have been shown to release restenosis inhibitors in their active forms.
1. A coated stent comprising:
a stent and
a coating composition comprising:
an HMG-CoA reductase inhibitor in an amount effective to inhibit proliferation of smooth muscle cells in a body lumen of a patient, and
a nonpolymeric carrier.
2. The coated stent of claim 1 wherein the carrier is a liquid at body temperature.
3. The coated stent of claim 2 wherein the carrier is a solid at room temperature.
4. The coated stent of claim 1 wherein the coating composition is a liquid at body temperature.
5. The coated stent of claim 4 wherein the coating composition is a solid at room temperature.
6. The coated stent of claim 1 wherein the coating composition further comprises:
a. a solvent and wherein the coating composition is a liquid at body temperature.
7. The coated stent of claim 1 wherein the coating composition is a solid at body temperature.
8. The coated stent of claim 1 wherein the coating composition comprises from about 1 wt % to about 50 wt % HMG-CoA reductase inhibitor, based on the total weight of the coating composition.
9. The coated stent of claim 1 wherein the coating composition comprises from about 5 wt % to about 30 wt % HMG-CoA reductase inhibitor, based on the total weight of the coating composition.
10. The coated stent of claim 1 wherein the coating composition comprises from about 10 wt % to about 20 wt % HMG-CoA reductase inhibitor, based on the total weight of the coating composition.
11. The coated stent of claim 1 wherein the HMG-CoA reductase inhibitor is selected from the group consisting of cerivastatin, atorvastatin, simvastatin, fluvastatin, lovastatin, and pravastatin.
12. The coated stent of claim 1 wherein the HMG-CoA reductase inhibitor is cerivastatin.
13. The coated stent of claim 1 wherein the coating composition further comprises:
a) a restenosis inhibitor which is not an HMG-CoA reductase inhibitor.
14. The coated stent of claim 1 wherein the carrier is non-reactive with the HMG-CoA reductase inhibitor.
15. A coated stent comprising a stent and a coating composition comprising a biologically active component and a nonpolymeric carrier component, the nonpolymeric carrier component having a melting point of about 50° C. or less and wherein the coating composition comprises the nonpolymeric carrier component by weight in the range from 50-99.9%.
16. The coated stent of claim 15 , further comprising a catheter, wherein the catheter and the coated stent can be coupled to form a treatment assembly.
17. The coated stent of claim 15 , wherein the carrier has a melting point of from about 35° C. to about 45° C.
18. The coated stent of claim 15 , wherein the biologically active component has a melting point of about 50° C. or less.
19. The coated stent of claim 15 , in which the coating composition is hydrophobic.
20. The coated stent of claim 15 , in which the nonpolymeric carrier component is hydrophobic.
21. The coated stent of claim 15 , in which the nonpolymeric carrier component is biodegradable.
22. The coated stent of claim 15 , in which the biologically active component is capable of inhibiting restenosis.
23. The coated stent of claim 15 , in which the biologically active component is selected from the group consisting of paclitaxel, actinomycin D, rapamycin, cerivastatin, fluvastatin, simvastatin, lovastatin, atorvastatin, and pravastatin.
24. The coated stent of claim 15 , wherein the stent comprises struts and the struts comprise capillaries, grooves, and channels engraved in the struts.
25. The coated stent of claim 15 , wherein the stent comprises a strut and the strut comprises a surface area enhancing feature.
26. The coated stent of claim 25 , wherein the surface enhancing feature is selected from the group consisting of grooves, capillaries, or channels.
27. The coated stent of claim 25 , wherein the surface enhancing feature contains at least some of the coating composition.
28. A coated stent comprising a stent and a coating composition that includes a biologically active component and a nonpolymeric carrier component, wherein the nonpolymeric carrier component has a viscosity of from about 0.1 to about 15000 cP and wherein the coating composition comprises a nonpolymeric carrier component by weight in the range from 50-99%.